Does NIA Spend Too Much On Alzheimer's?

Too Much On Alzheimer's? Author: Steven Benowitz Date: February 19, 1996 The National Institute on Aging (NIA) spent approximately $216 million last year-practically one-half of its 1995 total budget of $433 million-on research related to Alzheimer's disease. Overall, the National Institutes of Health funded some $311 million in Alzheimer's-associated work. Concerned: Richard Adelman worries about a lack of money for basic aging science. Is that too much? Is spending that much on Alzheimer'

Written bySteven Benowitz
| 8 min read

Register for free to listen to this article
Listen with Speechify
0:00
8:00
Share

Too Much On Alzheimer's? PDF Version
Author: Steven Benowitz
Date: February 19, 1996

The National Institute on Aging (NIA) spent approximately $216 million last year-practically one-half of its 1995 total budget of $433 million-on research related to Alzheimer's disease. Overall, the National Institutes of Health funded some $311 million in Alzheimer's-associated work.

Richard Adelman Concerned: Richard Adelman worries about a lack of money for basic aging science. Is that too much? Is spending that much on Alzheimer's work hurting studies in other areas of aging, such as basic biology?

Richard C. Adelman thinks so. Adelman, director of the Institute of Gerontology and a professor of biological chemistry at the University of Michigan, is concerned that NIA is focusing too many of its resources on Alzheimer's disease and not enough on the basic science of aging.

Yet Adelman doesn't blame NIA for carrying out a congressionally mandated mission to study Alzheimer's, which afflicts approximately 4 ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies